CN114231470B - Lactobacillus acidophilus capable of relieving ulcerative colitis and application thereof - Google Patents
Lactobacillus acidophilus capable of relieving ulcerative colitis and application thereof Download PDFInfo
- Publication number
- CN114231470B CN114231470B CN202210090844.4A CN202210090844A CN114231470B CN 114231470 B CN114231470 B CN 114231470B CN 202210090844 A CN202210090844 A CN 202210090844A CN 114231470 B CN114231470 B CN 114231470B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus acidophilus
- ulcerative colitis
- ccfm1200
- mice
- colon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 240000001046 Lactobacillus acidophilus Species 0.000 title claims abstract description 91
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 title claims abstract description 91
- 229940039695 lactobacillus acidophilus Drugs 0.000 title claims abstract description 91
- 206010009900 Colitis ulcerative Diseases 0.000 title claims abstract description 47
- 201000006704 Ulcerative Colitis Diseases 0.000 title claims abstract description 47
- 210000001072 colon Anatomy 0.000 claims abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 14
- 230000001965 increasing effect Effects 0.000 claims abstract description 10
- 150000004666 short chain fatty acids Chemical class 0.000 claims abstract description 7
- 229940088592 immunologic factor Drugs 0.000 claims abstract description 6
- 230000004580 weight loss Effects 0.000 claims abstract description 6
- 244000005700 microbiome Species 0.000 claims abstract description 5
- 239000006041 probiotic Substances 0.000 claims description 12
- 235000018291 probiotics Nutrition 0.000 claims description 12
- 230000000529 probiotic effect Effects 0.000 claims description 9
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 claims description 6
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 claims description 6
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims description 6
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 6
- 108020004999 messenger RNA Proteins 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000003028 elevating effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 2
- 241000699670 Mus sp. Species 0.000 abstract description 64
- 210000003608 fece Anatomy 0.000 abstract description 34
- 230000000968 intestinal effect Effects 0.000 abstract description 19
- 241000699666 Mus <mouse, genus> Species 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 14
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 102000009410 Chemokine receptor Human genes 0.000 abstract description 2
- 108050000299 Chemokine receptor Proteins 0.000 abstract description 2
- 239000000367 immunologic factor Substances 0.000 abstract description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 244000116699 Lactobacillus acidophilus NCFM Species 0.000 description 9
- 235000009195 Lactobacillus acidophilus NCFM Nutrition 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 8
- 238000012258 culturing Methods 0.000 description 8
- 108020004465 16S ribosomal RNA Proteins 0.000 description 7
- 241000588769 Proteus <enterobacteria> Species 0.000 description 6
- 229920003045 dextran sodium sulfate Polymers 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 238000009630 liquid culture Methods 0.000 description 5
- 238000000465 moulding Methods 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 241001052560 Thallis Species 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229960000633 dextran sulfate Drugs 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 238000011814 C57BL/6N mouse Methods 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000006872 mrs medium Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000033962 Fontaine progeroid syndrome Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000895503 Metrosideros Species 0.000 description 1
- 241000192142 Proteobacteria Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 241000196252 Ulva Species 0.000 description 1
- 241000405217 Viola <butterfly> Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940125698 hormone suppressant Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 210000005026 intestinal epithelial barrier Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses lactobacillus acidophilus capable of relieving ulcerative colitis and application thereof, and belongs to the technical field of microorganisms. The invention screens out a lactobacillus acidophilus CCFM1200, and the lactobacillus acidophilus CCFM1200 has the effect of relieving ulcerative colitis caused by DSS, and is specifically characterized in that: (1) reducing weight loss in ulcerative colitis mice; (2) Significantly increasing the colon length of ulcerative colitis mice; (3) Significantly increasing the level of immune factors in the colon of ulcerative colitis mice; (4) Significantly reducing the expression level of a cell chemokine receptor in the colon of a ulcerative colitis mouse; (5) The content of short chain fatty acid in the feces of ulcerative colitis mice is obviously improved; (6) modulation of ulcerative colitis mice intestinal flora. The lactobacillus acidophilus CCFM1200 has great application prospect in preparing medicines for preventing and/or treating ulcerative colitis.
Description
Technical Field
The invention relates to lactobacillus acidophilus capable of relieving ulcerative colitis and application thereof, in particular to a strain capable of relieving ulcerative colitis, and belongs to the technical field of microorganisms.
Background
Inflammatory Bowel Disease (IBD), which mainly includes Crohn's Disease (CD) and ulcerative colitis, is a chronic inflammation of the gut characterized by impaired intestinal epithelial barrier function and intestinal immune disorders. When the integrity of the intestinal epithelium is compromised, bacteria and their products in the intestine can penetrate the intestinal barrier, leading to abnormal immune responses and inflammation. In recent years, the number of people suffering from IBD in China has a rapid rising trend. At present, the cause of inflammatory bowel disease is not clear. The therapeutic drugs commonly used for inflammatory bowel disease are: aminosalicylic acid, hormones, and immunosuppressants. However, these three therapeutic modes have more side effects and limitations for treating inflammatory bowel disease.
In recent years, the use of probiotics for their use in alleviating inflammatory bowel disease has become a hotspot in research. There have been many studies showing that many probiotic strains have some degree of effect in alleviating inflammatory bowel disease. The probiotics can colonize in human body, change the intestinal flora composition of the host, and simultaneously produce beneficial metabolites so as to have beneficial effects on the host. Compared with the common medicines, the probiotics has the advantages of high safety, no side effect, no drug resistance, low cost and the like. Therefore, it is highly desirable to find a probiotic strain that can alleviate ulcerative colitis.
Disclosure of Invention
The invention provides a lactobacillus acidophilus (Lactobacillus acidophilus) CCFM1200 which is classified and named Lactobacillus acidophilus and is preserved in the microorganism strain preservation center of Guangdong province in 2021, 12 and 15 days, wherein the preservation number is GDMCC No. 62128, and the preservation address is the building 5 of the No. 59 of the 100 university of Mitsui in Guangzhou city.
In one embodiment, the 16S rDNA sequence of Lactobacillus acidophilus CCFM1200 is shown in SEQ ID NO.1, and colonies on MRS medium appear white, rough, and matt.
The invention also provides a probiotic containing the lactobacillus acidophilus CCFM1200.
In one embodiment, the probiotic agent has a viable count of Lactobacillus acidophilus CCFM1200 of no less than 1×10 9 CFU/mL or 1X 10 9 CFU/g。
In one embodiment, the probiotic is a bacterial suspension of lactobacillus acidophilus CCFM1200.
The invention also provides a starter containing the lactobacillus acidophilus CCFM1200.
In one embodiment, the method of preparing the starter is: inoculating lactobacillus acidophilus CCFM1200 into a culture medium, and culturing at 37 ℃ for 24-48 hours to obtain a culture solution; centrifuging the culture solution to obtain thalli; the thalli are resuspended by normal saline to obtain the ferment.
In one embodiment, the medium is MRS medium.
The invention also provides a medicine containing the lactobacillus acidophilus CCFM1200.
In one embodiment, the viable count of Lactobacillus acidophilus CCFM1200 in the medicament is not less than 1×10 9 CFU/mL or 1X 10 9 CFU/g。
In one embodiment, the medicament comprises the lactobacillus acidophilus CCFM1200 and a pharmaceutically acceptable carrier.
The invention also provides application of the lactobacillus acidophilus CCFM1200 in preparing a medicament for preventing and/or treating ulcerative colitis.
In one embodiment, the preventing and/or treating ulcerative colitis comprises at least one of the following actions:
(1) Relieving weight loss due to ulcerative colitis;
(2) Improving the reduction in colon length due to ulcerative colitis;
(3) Elevating immune factor IL-10 levels in the colon;
(4) Reducing the mRNA expression level of the cell chemokine receptors CCR2, CCR1 in the colon.
In one embodiment, the medicament is also for increasing short chain fatty acid content in the gut.
In one embodiment, the medicament is also for modulating intestinal flora.
In one embodiment, the modulating the intestinal flora comprises reducing the relative abundance of proteus in the intestinal flora.
In one embodiment, the modulating the intestinal flora comprises decreasing the relative abundance of escherchia_shigella in the intestinal flora.
The beneficial effects are that:
1. the invention screens out a lactobacillus acidophilus (Lactobacillus acidophilus) CCFM1200, and the lactobacillus acidophilus CCFM1200 has the effect of relieving ulcerative colitis caused by dextran sodium sulfate and is specifically characterized in that:
(1) Reducing weight loss in ulcerative colitis mice;
(2) The colon length of ulcerative colitis mice is obviously improved;
(3) Significantly increasing the level of immune factors in the colon of ulcerative colitis mice;
(4) The content of short chain fatty acid in the feces of ulcerative colitis mice is obviously improved;
(5) The intestinal flora diversity of ulcerative colitis mice is obviously improved;
(6) Reducing the relative abundance of proteus in the ulcerative colitis mouse intestinal flora;
(7) Reducing the relative abundance of escherchia_shigella in the intestinal flora of the ulcerative colitis mouse intestinal flora;
(8) Significantly reducing mRNA expression levels of cell chemokine receptors in the colon of ulcerative colitis mice;
based on the remission and therapeutic application of lactobacillus acidophilus CCFM1200 to ulcerative colitis mice, the lactobacillus acidophilus CCFM1200 has a huge application prospect in preparing medicines for preventing and/or treating ulcerative colitis.
2. The culture process of the lactobacillus acidophilus only needs the control of a culture medium and a plurality of culture conditions, has relatively low cost and is easy to realize industrial production.
Preservation of biological materials
Lactobacillus acidophilus (Lactobacillus acidophilus) CCFM1200, taxonomic designation Lactobacillus acidophilus, was deposited at the Cantonese microorganism culture Collection at 12 months 15 of 2021 under accession number GDMCC No. 62128 and at accession number Guangzhou Mitsui 100 university No. 59 building 5.
Drawings
Fig. 1: body weight change in mice of different groups.
Fig. 2: colon length status for different groups of mice.
Fig. 3: IL-10 content in the colon of different groups of mice.
Fig. 4: content of acetic acid in the faeces of different groups of mice.
Fig. 5: the content of butyric acid in the feces of different groups of mice.
Fig. 6: alpha-diversity Chao1 index of intestinal flora of different groups of mice.
Fig. 7: alpha-diversity Shannon index of intestinal flora in mice of different groups.
Fig. 8: the intestinal flora of mice in different groups is the relative abundance of the Proteus.
Fig. 9: the intestinal flora escherchia_shigella relative abundance of different groups of mice.
Fig. 10: relative expression of CCR2 mRNA in the colon of different groups of mice.
Fig. 11: relative expression of CCR1 mRNA in the colon of different groups of mice.
Detailed Description
The invention is further illustrated below in conjunction with specific embodiments and figures.
The C57BL/6N mice referred to in the examples below were purchased from Lehua corporation of Viola Zhejiang; sodium dextran sulfate referred to in the examples below was purchased from MP Biomedicals; lactobacillus acidophilus (Lactobacillus acidophilus) CCFM1200 as referred to in the examples below was isolated from the food institute biotechnology center at the university of Jiangnan; lactobacillus acidophilus NCFM was obtained from dupont chinese group limited; the study demonstrated that lactobacillus acidophilus NCFM strain is a type of probiotic bacteria present in healthy humans (mainly in the human gut environment). Since the isolation of lactobacillus acidophilus NCFM strain, extensive research has been conducted, which has effects in regulating and improving gastrointestinal function, enhancing immunity, alleviating ulcerative colitis, and the like. Lactobacillus acidophilus NCFM has become a commercial strain and the literature has reported that lactobacillus acidophilus NCFM has a beneficial effect in alleviating ulcerative colitis caused by sodium dextran sulfate. Therefore, lactobacillus acidophilus NCFM was used as a positive control for the strain in the following examples.
The detection reagents involved in the following examples were as follows:
ELISA kits for IL-10 (cat# DY 417) and IL-17 (cat# DY 421) were purchased from R & D Systems.
The following examples relate to the following media:
MRS solid medium: 10g/L peptone, 10g/L beef extract, 20g/L glucose, 2g/L sodium acetate, 5g/L yeast powder, 2g/L, K diammonium hydrogen citrate 2 PO 4 ·3H 2 O 2.6g/L、MgSO 4 ·7H 2 O 0.1g/L、MnSO 4 0.05g/L, tween 80 1mL/L, and agar 15g/L.
MRS liquid medium: 10g/L peptone, 10g/L beef extract, 20g/L glucose, 2g/L sodium acetate, 5g/L yeast powder, 2g/L, K diammonium hydrogen citrate 2 PO 4 ·3H 2 O 2.6g/L、MgSO 4 ·7H 2 O 0.1g/L、MnSO 4 0.05g/L, tween 80 1mL/L.
Example 1: screening and strain identification of lactobacillus acidophilus CCFM1200
1. Screening
Taking 0.5g of healthy human body feces sample from Ulva of Anhui province, adding 0.5g of sample stored in 30% (v/v) glycerol into a 10mL centrifuge tube containing 4.5mL of physiological saline under aseptic environment to obtain 10 -1 And (3) diluting the solution, repeating the diluting steps to sequentially obtain 10 -2 、10 -3 、10 -4 、10 -5 、10 -6 A dilution liquid; respectively sucking 100 mu L of gradient diluents with different gradients, coating the gradient diluents on an MRS solid culture medium, and culturing for 72 hours at 37 ℃ to obtain a diluted coating plate; representative colonies on the dilution-plated plates were picked and streaked onto MRS solid media,culturing for 48 hours at 37 ℃ to obtain purified bacterial colonies; the purified colony is picked and inoculated into MRS liquid culture medium, and is cultured for 48 hours at 37 ℃ to obtain the strain CCFM1200.
2. Authentication
The genome of CCFM1200 is extracted, the 16S rDNA of CCFM1200 is amplified and sequenced (by the Souzhou Jin Weizhi biotechnology Co., ltd.), and the 16S rDNA sequence of CCFM1200 obtained by sequencing analysis (the 16S rDNA sequence of CCFM1200 is shown as SEQ ID NO. 1) is aligned in GenBank, and the result shows that the strain is lactobacillus acidophilus and named as lactobacillus acidophilus (Lactobacillus acidophilus) CCFM1200.
Example 2: preparation of Lactobacillus acidophilus suspension
The preparation method of lactobacillus acidophilus NCFM or lactobacillus acidophilus CCFM1200 bacterial liquid comprises the following steps:
dipping lactobacillus acidophilus bacterial liquid, streaking on an MRS solid culture medium, and culturing at 37 ℃ for 48 hours to obtain a single colony;
picking single bacterial colony, inoculating into MRS liquid culture medium, culturing at 37deg.C for 24 hr to obtain activating solution; inoculating the activating solution into MRS liquid culture medium according to the inoculum size of 1% (v/v), and culturing at 37 ℃ for 24 hours to obtain first-stage seed solution;
inoculating the first-level seed liquid into MRS liquid culture medium according to an inoculum size of 1% (v/v), and culturing at 37 ℃ for 24 hours to obtain a second-level seed liquid;
inoculating the secondary seed solution into MRS liquid culture medium according to the inoculum size of 1% (v/v), and culturing at 37 ℃ for 24 hours to obtain bacterial solution; centrifuging 6000g of bacterial liquid for 15min, and collecting precipitate; washing the precipitate with physiological saline buffer solution twice, and centrifuging 6000g for 10min again to obtain thalli; the lactobacillus is resuspended to a cell concentration of 1×10 by using physiological saline 9 CFU/mL to obtain lactobacillus acidophilus bacterial liquid.
Example 3: effect of Lactobacillus acidophilus CCFM1200 on weight and colon length of ulcerative colitis mice
Taking 32 male pathogen free (SPF) C57BL/6N mice of 6-8 weeks old, feeding for 1 week under the conditions of 22-24 ℃ of room temperature, 40-60% of humidity, 12h/12h day-night alternation, free feeding and drinking water, and randomly dividing into 4 groups of 8 mice each, wherein the 4 groups are respectively: control, make module, lactobacillus acidophilus (Lactobacillus acidophilus) NCFM, lactobacillus acidophilus (Lactobacillus acidophilus) CCFM1200.
The experiments were started after 1 week of adaptive feeding for 2 weeks. The specific treatment is as follows:
control group: normal drinking of mice in the whole experimental period, and filling of 200 mu L of physiological saline as a control;
and (5) manufacturing a module: normal drinking water is carried out on days 1-7, 2.5% (w/v) dextran sodium sulfate solution is drunk from day 8, molding is finished, 7 days are continued, and 200 mu L of physiological saline is filled in the stomach in the whole experimental process;
lactobacillus acidophilus NCFM group: normal drinking water on days 1-7, drinking 2.5% (w/v) dextran sodium sulfate solution from day 8, molding, and filling 200 μl of bacterial suspension into mice every day during the whole experiment to obtain a gastric lavage dosage of 1×10 9 CFU/day only.
Lactobacillus acidophilus CCFM1200 group: normal drinking water on days 1-7, drinking 2.5% (w/v) dextran sodium sulfate solution from day 8, molding, and filling 200 μl of bacterial suspension into mice every day during the whole experiment to obtain a gastric lavage dosage of 1×10 9 CFU/day only.
During and after the molding, the weight of each group of mice is measured by a weight meter; after the experiment is finished, the colon of the mouse is taken, the length of the colon of the mouse is measured, and the measurement results are respectively shown in figures 1-2.
As can be seen from fig. 1, the weight ratios (the ratio of the weight of day 7 to the weight of day 1) of the mice in the control group, the model group, the NCFM group, and the CCFM1200 group were 1.02, 0.91, 0.93, and 0.94, respectively, from the model to day 7. The NCFM group and the CCFM1200 group can reduce weight loss of mice under sodium dextran sulfate modeling.
As can be seen from fig. 2, the colon length of control and CCFM1200 mice was significantly higher than that of the model mice (122% and 115%, respectively), but the colon length of the NCFM mice was not significantly different from that of the model mice. It can be seen that lactobacillus acidophilus CCFM1200 can alleviate weight loss in ulcerative colitis mice, significantly improve symptoms of reduced colon length, and has better effect than lactobacillus acidophilus (Lactobacillus acidophilus) NCFM.
Example 4: effect of Lactobacillus acidophilus CCFM1200 on immune factor levels in the colon of ulcerative colitis mice
Grouping and modeling of mice was the same as in example 3. After the experiment is finished, the mice are killed, the colon of the mice is placed in phosphate buffer solution and homogenized, the content of IL-10 in the colon homogenate of each group of mice is measured by ELISA kit, and the detection result is shown in figure 3.
As shown in FIG. 3, the concentration of IL-10 in the colon of the control mice was 26.22pg/mg protein, and the IL-10 level of the model group was decreased as compared with the control mice, and the concentration was 14.05pg/mg protein. Compared with the model mice, the IL-10 level in the colon of the NCFM group and the CCFM1200 group mice is obviously improved, 36.18pg/mg protein and 44.55pg/mg protein are respectively obtained, and the effect of the CCFM1200 group is obviously better than that of the NCFM group.
It can be seen that lactobacillus acidophilus (Lactobacillus acidophilus) CCFM1200 can increase the level of the immune factor IL-10 in the colon of ulcerative colitis mice and is superior to lactobacillus acidophilus (Lactobacillus acidophilus) NCFM.
Example 5: effect of Lactobacillus acidophilus CCFM1200 on short chain fatty acid content in ulcerative colitis mouse feces
Grouping and modeling of mice was the same as in example 3. After the experiment is finished, collecting the mouse feces, placing the mouse feces in liquid nitrogen, transferring the liquid nitrogen to a refrigerator at the temperature of minus 80 ℃, taking out the mouse feces before detecting the content of the short-chain fatty acid, carrying out vacuum freeze-drying, accurately weighing 0.05g of freeze-dried feces sample, dissolving the feces sample in 0.5mL of saturated sodium chloride solution, soaking the feces sample for 30min, homogenizing the feces sample by a tissue homogenizer, adding 0.02mL of 10% sulfuric acid, vibrating the feces sample for 30s, accurately adding 0.8mL of diethyl ether solution into the feces solution in a fume hood, vibrating the feces sample for 30s, centrifuging the feces sample for 15min (8000 g and 4 ℃), transferring the supernatant to a centrifuge tube containing 0.25g of anhydrous sodium sulfate, vibrating the feces sample uniformly, centrifuging the feces sample for 15min (8000 g and 4 ℃), taking the supernatant to a gas quality bottle, and detecting the content of the short-chain fatty acid by GCMS, wherein the detection results are shown in figures 4 and 5.
As shown in FIGS. 4 and 5, acetic acid and butyric acid (46.77. Mu. Mol/g, 37.38. Mu. Mol/g, respectively) were decreased in the faeces of the model mice compared to the control mice (54.69. Mu. Mol/g, 46.04. Mu. Mol/g, respectively); the content of acetic acid and butyric acid (77.74. Mu. Mol/g, 59.15. Mu. Mol/g) in the faeces of the CCFM1200 mice was significantly up-regulated compared to the model building group; the amounts of acetic acid and butyric acid in the feces of the NCFM group mice were not significantly different from the model building group.
It can be seen that lactobacillus acidophilus (Lactobacillus acidophilus) CCFM1200 significantly increases the content of acetic acid and butyric acid in the feces of ulcerative colitis mice, whereas lactobacillus acidophilus (Lactobacillus acidophilus) NCFM does not have this effect.
Example 6: effect of Lactobacillus acidophilus CCFM1200 on intestinal flora diversity in ulcerative colitis mice
Grouping and modeling of mice was the same as in example 3. After the completion of the experiment, the mouse feces was collected, genomic DNA was extracted from the feces by the FastDNA non-Spin Kit (MP biosciences, USA), and V3-V4 of the extracted genomic DNA was obtained
The regions were subjected to specific PCR amplification, 16S rDNA sequencing, and the changes in fecal flora alpha diversity (Chao 1 and Shannon) were analyzed, and the analysis results are shown in FIGS. 6 and 7.
As can be seen from fig. 6, regarding the Chao1 index, there was no significant difference between lactobacillus acidophilus (Lactobacillus acidophilus) NCFM (47.25), lactobacillus acidophilus (Lactobacillus acidophilus) CCFM1200 (50.875) and the model building group (24.38), which significantly improved the diversity of the intestinal tract population of mice.
As can be seen from fig. 7, lactobacillus acidophilus (Lactobacillus acidophilus) NCFM (2.84), lactobacillus acidophilus (Lactobacillus acidophilus) CCFM1200 (2.80) also significantly increased the diversity of the mouse intestinal tract population relative to the control group (2.25) and the model group (2.52) in terms of Shannon index.
Example 7: influence of Lactobacillus acidophilus CCFM1200 on the ulcerative colitis mice intestinal Proteobacteria
Grouping and modeling of mice was the same as in example 3. After the experiment, mouse feces were collected, genomic DNA in the feces was extracted by FastDNA Spin Kit (MP biomedical Co., USA), and the V3-V4 region of the extracted genomic DNA was subjected to specific PCR amplification, 16S rDNA sequencing, and the change of Proteus in the feces flora was analyzed, and the analysis result was shown in FIG. 8.
As can be seen from fig. 8, the abundance of proteus in the feces of the model mice (4.65%) was significantly increased relative to the control (0.52%). Lactobacillus acidophilus (Lactobacillus acidophilus) NCFM (2.61%), lactobacillus acidophilus (Lactobacillus acidophilus) CCFM1200 (2.50%) was able to down-regulate the relative abundance of proteus phylum in mouse faeces by 2.04% and 2.15%, respectively.
Example 8: effect of Lactobacillus acidophilus CCFM1200 on ulcerative colitis mice intestinal Escherchia_Shigella
Grouping and modeling of mice was the same as in example 3. After the completion of the experiment, the mouse feces was collected, genomic DNA was extracted from the feces by the FastDNA Spin Kit (MP biosciences, USA), and V3-V4 of the extracted genomic DNA was obtained
The region was subjected to specific PCR amplification, 16S rDNA sequencing, analysis of Escherchia_Shigella changes in fecal flora, and the analysis results are shown in FIG. 9.
As can be seen from fig. 9, the relative abundance of escherchia_shigella (3.12%) in the mouse feces of the model group was increased by 2.74% relative to the control group (0.38%). Lactobacillus acidophilus (Lactobacillus acidophilus) NCFM (0.34%), lactobacillus acidophilus (Lactobacillus acidophilus) CCFM1200 (0.38%) was able to down-regulate the relative abundance of escherchia_shigella in mouse faeces by 2.78% and 2.74%, respectively.
Example 9: effect of Lactobacillus acidophilus CCFM1200 on expression levels of CCR2 and CCR1 in the intestine of ulcerative colitis mice
Grouping and modeling of mice was the same as in example 3. After the experiment is finished, the mice are killed, the colon of the mice is taken to extract RNA, the kit is used for reverse transcription, the expression level of cell chemokines CCR2 and CCR1 in the colon of each group of mice is measured, and the detection results are shown in figures 10-11.
As shown in fig. 10, the expression level of CCR2 in colon region of mice after DSS modeling was significantly increased compared to mice in the blank group. After being treated by lactobacillus acidophilus NCFM and lactobacillus acidophilus CCFM1200, the relative expression quantity is obviously reduced by 71.67 percent and 84.41 percent compared with the molding components.
As shown in fig. 11, the CCR1 expression level at the colon region of mice after DSS modeling was significantly increased compared to the mice in the blank group. After the NCFM treatment, the relative expression quantity of the lactobacillus acidophilus is reduced by 44.21 percent compared with that of a modeling module. After being treated by lactobacillus acidophilus CCFM1200, the relative expression quantity is obviously reduced by 54.83 percent compared with a modeling module.
While the invention has been described with reference to the preferred embodiments, it is not limited thereto, and various changes and modifications can be made therein by those skilled in the art without departing from the spirit and scope of the invention as defined in the appended claims.
SEQUENCE LISTING
<110> university of Jiangnan
<120> Lactobacillus acidophilus capable of relieving ulcerative colitis and application thereof
<130> BAA211620A
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 1430
<212> DNA
<213> Lactobacillus acidophilus
<400> 1
tgcagtcgag cgagctgaac caacagattg cacttcggtg atgacgttgg gaacgcgagc 60
ggcggatggg tgagtaacac gtggggaacc tgccccatag tctgggatac cacttggaaa 120
caggtgctaa taccggataa gaaagcagat cgcatgatca gcttataaaa ggcggcgtaa 180
gctgtcgcta tgggatggcc ccgcggtgca ttagctagtt ggtagggtaa cggcctacca 240
aggcaatgat gcatagccga gttgagagac tgatcggcca cattgggact gagacacggc 300
ccaaactcct acgggaggca gcagtaggga atcttccaca atggacgaaa gtctgatgga 360
gcaacgccgc gtgagtgaag aaggttttcg gatcgtaaag ctctgttgtt ggtgaagaag 420
gatagaggta gtaactggcc tttatttgac ggtaatcaac cagaaagtca cggctaacta 480
cgtgccagca gccgcggtaa tacgtaggtg gcaagcgttg tccggattta ttgggcgtaa 540
agcgagcgca ggcggaagaa taagtctgat gtgaaagccc tcggcttaac cgaggaactg 600
catcggaaac tgtttttctt gagtgcagaa gaggagagtg gaactccatg tgtagcggtg 660
gaatgcgtag atatatggaa gaacaccagt ggcgaaggcg gctctctggt ctgcaactga 720
cgctgaggct cgaaagcatg ggtagcgaac aggattagat accctggtag tccatgccgt 780
aaacgatgag tgctaagtgt tgggaggttt ccgcctctca gtgctgcagc taacgcatta 840
agcactccgc ctggggagta cgaccgcaag gttgaaactc aaaggaattg acgggggccc 900
gcacaagcgg tggagcatgt ggtttaattc gaagcaacgc gaagaacctt accaggtctt 960
gacatctagt gcaatccgta gagatacgga gttcccttcg gggacactaa gacaggtggt 1020
gcatggctgt cgtcagctcg tgtcgtgaga tgttgggtta agtcccgcaa cgagcgcaac 1080
ccttgtcatt agttgccagc attaagttgg gcactctaat gagactgccg gtgacaaacc 1140
ggaggaaggt ggggatgacg tcaagtcatc atgcccctta tgacctgggc tacacacgtg 1200
ctacaatgga cagtacaacg aggagcaagc ctgcgaaggc aagcgaatct cttaaagctg 1260
ttctcagttc ggactgcagt ctgcaactcg actgcacgaa gctggaatcg ctagtaatcg 1320
cggatcagca cgccgcggtg aatacgttcc cgggccttgt acacaccgcc cgtcacacca 1380
tgggagtctg caatgcccaa agccggtggc ctaaccttcg ggaaggagcc 1430
Claims (9)
1. Lactobacillus acidophilus (Lactobacillus acidophilus) CCFM1200 was deposited at the Cantonese microorganism strain collection at 12 and 15 of 2021 under the accession number GDMCC No. 62128.
2. A probiotic comprising lactobacillus acidophilus CCFM1200 as claimed in claim 1.
3. The probiotic preparation according to claim 2, characterized in that the viable count of lactobacillus acidophilus CCFM1200 in the probiotic preparation is not less than 1 x 10 9 CFU/mL or 1X 10 9 CFU/g。
4. A medicament comprising lactobacillus acidophilus CCFM1200 as claimed in claim 1.
5. The medicament according to claim 4, which comprises lactobacillus acidophilus CCFM1200 according to claim 1 and a pharmaceutically acceptable carrier.
6. The medicament according to claim 4 or 5, wherein the viable count of lactobacillus acidophilus CCFM1200 is not less than 1 x 10 9 CFU/mL or 1X 10 9 CFU/g。
7. Use of lactobacillus acidophilus CCFM1200 as claimed in claim 1 in the manufacture of a medicament for the prevention and/or treatment of ulcerative colitis.
8. The use according to claim 7, wherein said prevention and/or treatment of ulcerative colitis refers to at least one of the following actions:
(1) Relieving weight loss due to ulcerative colitis;
(2) Improving the reduction in colon length due to ulcerative colitis;
(3) Elevating immune factor IL-10 levels in the colon;
(4) Reducing the mRNA expression level of the cell chemokine receptors CCR2, CCR1 in the colon.
9. The use according to claim 8, wherein the medicament is further for increasing the short chain fatty acid content in the intestinal tract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210090844.4A CN114231470B (en) | 2022-01-26 | 2022-01-26 | Lactobacillus acidophilus capable of relieving ulcerative colitis and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210090844.4A CN114231470B (en) | 2022-01-26 | 2022-01-26 | Lactobacillus acidophilus capable of relieving ulcerative colitis and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114231470A CN114231470A (en) | 2022-03-25 |
| CN114231470B true CN114231470B (en) | 2023-04-28 |
Family
ID=80747222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210090844.4A Active CN114231470B (en) | 2022-01-26 | 2022-01-26 | Lactobacillus acidophilus capable of relieving ulcerative colitis and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114231470B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114672436B (en) * | 2022-04-07 | 2024-04-16 | 重庆医科大学 | Lactobacillus acidophilus and application thereof |
| CN114990030B (en) * | 2022-07-18 | 2022-11-18 | 微康益生菌(苏州)股份有限公司 | Lactobacillus acidophilus LA18 and application thereof in preparing product for regulating intestinal flora or immunoregulation |
| CN115177642B (en) * | 2022-08-05 | 2023-05-30 | 皖南医学院第一附属医院（皖南医学院弋矶山医院） | Composition for regulating intestinal flora of ulcerative colitis and preparation method and application thereof |
| CN115501259B (en) * | 2022-09-22 | 2023-04-21 | 东北农业大学 | Composition for relieving ulcerative colitis and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105327338B (en) * | 2015-11-23 | 2018-11-23 | 东北农业大学 | A kind of drug and preparation method thereof for treating ulcerative colitis |
| CN105343133B (en) * | 2015-12-08 | 2019-11-19 | 东北农业大学 | A kind of compound probiotic that treating ulcerative colitis, drug and preparation method thereof |
| CN110023486B (en) * | 2016-12-20 | 2022-02-22 | 深圳华大生命科学研究院 | Lactobacillus acidophilus and culture method and application thereof |
-
2022
- 2022-01-26 CN CN202210090844.4A patent/CN114231470B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN114231470A (en) | 2022-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114231470B (en) | Lactobacillus acidophilus capable of relieving ulcerative colitis and application thereof | |
| CN114574390B (en) | Bifidobacterium longum subspecies infantis for relieving colonitis and application thereof | |
| WO2022110727A1 (en) | Application of lactobacillus paracasei et-22 in improving intestinal bacterial infection resistance and intestinal immunity | |
| CN113832077B (en) | Lactobacillus rhamnosus and application thereof | |
| CN113005049B (en) | Bifidobacterium breve capable of relieving diarrhea and application thereof | |
| CN113897302B (en) | Bifidobacterium capable of relieving colitis and application thereof | |
| CN112458007A (en) | Lactobacillus crispatus for preventing and/or treating diseases related to genital tract flora disorder | |
| CN114292781B (en) | Bifidobacterium longum SYSU-02 and application thereof | |
| WO2021143621A1 (en) | Anaerostipes sp b2131 strain and use thereof in inflammatory bowel diseases | |
| CN112940985A (en) | Lactobacillus rhamnosus preparation for enhancing human immunity and preparation method thereof | |
| CN115029260B (en) | Lactobacillus gasseri with anti-inflammatory and antioxidant properties and application thereof | |
| CN114774315B (en) | Application of lactobacillus rhamnosus strain LRa05 in preparation of immunity enhancing product and/or eczema relieving product | |
| CN114317334B (en) | Lactobacillus sake capable of co-aggregating with helicobacter pylori and application thereof | |
| CN110591986B (en) | Lactobacillus casei capable of relieving rheumatoid arthritis and application thereof | |
| CN116445356B (en) | Bifidobacterium animalis subspecies BA67 for regulating intestinal flora and enhancing immunity and application thereof | |
| CN115044504B (en) | Enterococcus faecalis YZ-1 and probiotic application thereof | |
| CN110141584B (en) | Application of Lactobacillus kefir M11 in bacteriostasis and active ingredient of medicament for treating type II diabetes | |
| CN117143767A (en) | Breast milk-derived fermented lactobacillus mucilaginosus MSJK0025 capable of regulating intestinal flora and application thereof | |
| CN116083327A (en) | Bifidobacterium longum subspecies infantis and use thereof for relieving constipation, preventing inflammation of colonic tissue and improving intestinal flora | |
| CN112980737B (en) | Bifidobacterium adolescentis for promoting proliferation of animal bifidobacterium and application thereof | |
| CN115820488A (en) | Bifidobacterium longum subspecies neonatorum capable of adjusting Th1/Th2 balance and IgA synthesis of young mice and application thereof | |
| CN112538441B (en) | Lactobacillus reuteri CCFM1144 for relieving diarrhea caused by ETEC and application thereof | |
| CN114806953A (en) | Lactobacillus gasseri with characteristic of improving type 1 diabetes | |
| CN116496938B (en) | Lactobacillus acidophilus MY2 for producing hyaluronic acid and application thereof in preparation of anti-aging and whitening food and medicines | |
| CN115786175B (en) | Lactobacillus mucosae and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |